<div id="readability-page-1">New activity is brewing for Centessa Pharmaceuticals ( (CNTA) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn more about the proposed company action.<h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul> Centessa Pharmaceuticals has called special shareholder meetings on June 12, 2026 in London to vote on a proposed acquisition by Eli Lilly, to be implemented via a court-sanctioned scheme of arrangement under U.K. company law. Ordinary shareholders and ADS holders are being asked to approve the scheme and a related special resolution authorizing board actions and amendments to the company’s articles to enable the deal. Under the terms of the transaction, Centessa investors would receive $38.00 in cash per ordinary share or ADS plus a non-transferable contingent value right worth up to an additional $9.00 per share or ADS if specified milestones are met. The board, acting on legal and financial advice, has unanimously endorsed the deal as being in the best interests of shareholders, and completion would see Centessa become a Lilly subsidiary, ending its independent listing and crystallizing value for holders subject to the outcome of the votes and court approval. The most recent analyst rating on (CNTA) stock is a Hold with a $42.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page. Spark’s Take on CNTA Stock According to Spark, TipRanks’ AI Analyst, CNTA is a Neutral. The score is driven by the announced Lilly acquisition (supportive near-term value anchor) and strong technical momentum, partially offset by weak operating performance with ongoing losses and cash burn, and limited traditional valuation support due to negative earnings. To see Spark’s full report on CNTA stock, click here. More about Centessa Pharmaceuticals Centessa Pharmaceuticals is a U.K.-incorporated biopharmaceutical company focused on developing clinical-stage drug candidates, including sleep and orexin-related therapies such as cleminorexton (formerly ORX750), ORX142 and ORX489. Its shares trade both as ordinary shares in the U.K. register and as American Depositary Shares on Nasdaq, giving it exposure to global healthcare and life sciences investors. Average Trading Volume: 2,617,039 Technical Sentiment Signal: Buy Current Market Cap: $5.91B </div>

CNTA

ARKG

Centessa Pharmaceuticals has scheduled a shareholder vote on June 12, 2026, regarding a proposed acquisition by Eli Lilly. Shareholders will vote on receiving $38 per share in cash, plus a contingent value right worth up to $9 if certain milestones are met. The board supports the deal, which would make Centessa a subsidiary of Lilly. Analysts currently rate CNTA stock as a Hold with a price target of $42, reflecting a neutral outlook due to the acquisition and ongoing financial challenges.

Tip Ranks

Centessa Pharmaceuticals

Eli Lilly

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VG Health

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

iShares Biotechnology ETF

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Defiance Daily Target 2X Long LLY ETF

Health Care Select Sector SPDR

Centessa Sets June Vote on $38-Per-Share Eli Lilly Takeover with Added CVR Upside